| |
|
|
|
NeuBase Therapeutics Inc.  
|
|
8.44 -0.21 (-0.02%) |
09-17 16:00 |
|
Open: |
8.65 |
Pre close: |
8.65 |
Target:
|
10.24 
|
|
High: |
8.82 |
Low: |
8.27 |
Resistance:
|
8.77
9.77
|
|
Volume: |
431,998 |
Market Cap: |
205M |
Support:
|
7.14
5.94
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
8.82
|
MACD |
MACD(12,26):
|
0.15 |
|
MA(20): |
8.40 |
Signal(12,26,9): |
0.11  |
|
MA(100): |
8.36 |
Stochastic Oscillator |
%K(14,3):
|
57.41 |
|
MA(250): |
7.19 |
%D(3): |
69.47 |
|
Average Volume(K) |
3-Month: |
26980
|
52-Week |
High:
|
11.78 |
|
10-Days: |
31048 |
Low: |
4.15 |
|
RSI |
RSI(14):
|
50.59 |
Change(%): |
28.1 |
|
Financials, Statistics and Valuation |
|
EPS |
-3.260 |
Return on Equity (ttm) |
0.0 |
Shares Out. (M) |
23.12 |
|
EPS Est. Current Year |
0.000 |
Return on Assets (ttm) |
0.0 |
Shares Float (M) |
15.72 |
|
EPS Est. Next Year |
0.000 |
PEG Ratio |
0.00 |
% Held by Insiders |
21.80 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
16.92 |
|
Forward EPS |
-3.260 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
1070 |
|
Book Value (p.s.) |
0.590 |
EBITDA (p.s.) |
-1.409 |
P/E |
-2.59 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
14.31 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-9.59 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
0.00 |
P/CF |
-20.35 |
|
|
|
|
|
|
